Coronavirus Outbreak: Antiviral drug Umifenovir to undergo clinical trial in CSIR institute, says health ministry

Union Health Minister Harsh Vardhan said that the drug Umifenovir prevents the entry of the COVID-19 into human cells and also acts by priming the immune system.

Asian News International June 19, 2020 10:59:19 IST
Coronavirus Outbreak: Antiviral drug Umifenovir to undergo clinical trial in CSIR institute, says health ministry

New Delhi: CSIR constituent lab CSIR-Central Drug Research Institute (CDRI) Lucknow has received permission for carrying out Phase III trial of antiviral drug Umifenovir, Union Health Minister Dr Harsh Vardhan said on Friday.

 <span class=Coronavirus Outbreak Antiviral drug Umifenovir to undergo clinical trial in CSIR institute says health ministry" width="640" height="362" />

Representational image. AP

"CSIR constituent lab CSIR-Central Drug Research Institute (CDRI) Lucknow, has received permission for carrying out Phase III randomised, Double-blind, Placebo-controlled trial of efficacy, safety and tolerability of antiviral drug Umifenovir," the Union Health Minister tweeted.

"The Phase III Clinical Trials will be carried out at King George's Medical University (KGMU), Dr Ram Manohar Lohia Institute of Medical Sciences (RMLIMS) and ERA's Lucknow Medical College and Hospital, Lucknow," he said in another tweet.

The minister said that the drug prevents the entry of the virus into human cells and also acts by priming the immune system.

"This drug has a good safety profile and acts by preventing entry of the virus into human cells and also by priming the immune system. Umifenovir is mainly used for the treatment of influenza and has recently come into prominence due to its potential use for COVID-19 patients," he added.

Updated Date:

also read

India logs 14,306 new COVID-19 cases, 443 fresh fatalities; number of vaccines administered crosses 102 crore
India

India logs 14,306 new COVID-19 cases, 443 fresh fatalities; number of vaccines administered crosses 102 crore

The active cases comprise 0.49 percent of the total infections, the lowest since March 2020, while the national recovery rate is at 98.18 percent, highest since March 2020

India registers 13,451 new COVID-19 infections, 585 deaths; active cases lowest in 242 days
India

India registers 13,451 new COVID-19 infections, 585 deaths; active cases lowest in 242 days

The active cases comprise 0.48 percent of the total infections, the lowest since March 2020, while the national COVID-19 recovery rate was recorded at 98.19 percent, the highest since March 2020

Over 96 crore COVID-19 vaccine doses administered in India, says Union health ministry
India

Over 96 crore COVID-19 vaccine doses administered in India, says Union health ministry

The daily vaccination tally is expected to increase with the compilation of the final reports for the day by late night, the ministry said